Stockscreener 앱 받기
0.1328
0.00%
0.000100
전일 마감가:
$0.1327
열려 있는:
$0.135
하루 거래량:
489.73K
Relative Volume:
0.81
시가총액:
$16.80M
수익:
-
순이익/손실:
$-21.91M
주가수익비율:
-0.0891
EPS:
-1.49
순현금흐름:
-
1주 성능:
-78.25%
1개월 성능:
-74.49%
6개월 성능:
-94.47%
1년 성능:
-94.45%
1일 변동 폭
$0.1299
$0.135
1주일 범위
$0.115
$0.164
52주 변동 폭
$0.115
$3.55
Incannex Healthcare Inc Stock (IXHL) Company Profile
명칭
Incannex Healthcare Inc
전화
61 409 840 786
주소
401 DOCKLANDS DRIVE, DOCKLANDS, VICTORIA
IXHL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
0.1328 | 16.80M | 0 | -21.91M | 0 | -1.49 |
|
ZTS
Zoetis Inc
|
157.37 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.36 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.59 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.42 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
296.07 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Incannex Healthcare Inc 주식(IXHL)의 최신 뉴스
Incannex Healthcare Inc [IXHL] Revenue clocked in at $0.10 million, down -92.83% YTD: What’s Next? - dbtnews.com
It makes sense and dollars to buy Incannex Healthcare Inc (IXHL) stock - Sete News
Analyzing the Impact of Earnings Reports on Incannex Healthcare Inc Inc. (IXHL) Price Performance - investchronicle.com
Is Incannex Healthcare Inc (NASDAQ:IXHL) stock a better investment at this time? - uspostnews.com
Trading Day Review: Incannex Healthcare Inc (IXHL) Gains Momentum, Closing at 0.61 - DWinneX
Incannex Healthcare (NASDAQ:IXHL) Trading Down 19% – Here’s Why - Defense World
Incannex enters agreement for potential stock sales By Investing.com - Investing.com India
Incannex enters agreement for potential stock sales - Investing.com Australia
IXHL Stock Touches 52-Week Low at $0.64 Amid Market Challenges - Investing.com
Incannex Healthcare Completes Phase 2 Enrollment In Reposa Phase 2/3 Trial Of Ihl-42X, An Oral Once-Daily Treatment For Obstructive Sleep Apnea (Osa) - MarketScreener
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) - TradingView
IXHL stock touches 52-week low at $0.73 amid market challenges - Investing.com
Incannex Healthcare files to sell 65.97M shares of common stock for holders - MSN
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Decrease in Short Interest - The AM Reporter
Incannex Healthcare Repays Convertible Debenture in Full - TipRanks
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
IXHL Stock Touches 52-Week Low at $0.73 Amid Market Challenges - Investing.com Australia
IXHL Stock Touches 52-Week Low at $0.73 Amid Market Challenges By Investing.com - Investing.com South Africa
Incannex Healthcare announces $12.5 million offering - Green Market Report
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules - The Manila Times
Incannex Healthcare Inc. Announces Pricing Of $12.5 Million Private Placement Priced At The Market Under Nasdaq Rules - Marketscreener.com
Incannex Healthcare Inc. Announces $12.5 Million Offering of Common Stock and Series A Warrants - Nasdaq
Can This $12.5M Deal Push Incannex's Sleep Apnea Treatment to Phase 3? - StockTitan
IXHL stock touches 52-week low at $1.09 amid market challenges - Investing.com Australia
Incannex OSA Drug Candidate IHL-42X Sails Through Milestones - Sleep Review
IXHL stock touches 52-week low at $1.49 amid market challenges By Investing.com - Investing.com South Africa
IXHL stock touches 52-week low at $1.49 amid market challenges - Investing.com UK
Incannex Healthcare Limited Reports Quarterly Financials - TipRanks
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025 - The Kingston Whig-Standard
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates - Defense World
Incannex Healthcare Reports Fiscal Second Quarter Results -February 14, 2025 at 08:49 am EST - Marketscreener.com
Incannex Healthcare Inc. SEC 10-Q Report - TradingView
Incannex Healthcare Appoints Alison Wimms, Ph.D. to its Newly Formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board - Defense World
Incannex Forms Clinical Advisory Board to Guide IHL-42X Sleep Apnea Drug Development - Sleep Review
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board - The Manila Times
Incannex Healthcare Inc. Announces the Appointment of Alison Wimms as an Advisor to Its Newly Formed Ihl-42X Obstructive Sleep Apnea Clinical Advisory Board - Marketscreener.com
Sleep Medicine Pioneer Joins Incannex's Revolutionary OSA Treatment Development - StockTitan
Incannex Healthcare Announces Positive Topline Results from PK Study - Defense World
Incannex Reports Positive Data for OSA Drug Candidate IHL-42X - Sleep Review
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea - The Manila Times
Incannex Reports Strong Results for Sleep Apnea Drug IHL-42X in Key Clinical Study - StockTitan
Incannex Healthcare faces Nasdaq delisting over market value By Investing.com - Investing.com South Africa
Incannex Healthcare faces Nasdaq delisting over market value - Investing.com
Incannex Healthcare Inc (IXHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.87%
자본화:
|
볼륨(24시간):